When given together with VistaGen's oral prodrug AV-101, probenecid increased brain concentrations of AV-101 7-fold and its active metabolite, 7-CI-KYNA, 35-fold SOUTH SAN FRANCISCO, Calif., Feb. 11, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical

Company also Receives a Notice of Allowance from the USPTO for a New AV-101 U.S. Patent for Treatment of Dyskinesia Induced by Levodopa Therapy SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing

Multiple electrophysiological biomarkers indicate AV-101's NMDA receptor target engagement Both AV-101 doses were well-tolerated and not associated with dissociative or serious adverse events Poster presented at 2019 Annual Meeting of American College of Neuropsychopharmacology SOUTH SAN FRANCISCO,

VistaGen's PH94B is the first drug candidate to be granted U.S. FDA Fast Track designation for treatment of social anxiety disorder SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 /PRNewswire/ --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced topline results from the

SOUTH SAN FRANCISCO, Calif., Nov. 7, 2019 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced financial results for its

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that the European Patent

Company on Track to Report Top Line Results Before Year End SOUTH SAN FRANCISCO, Calif., Oct. 8, 2019 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with

Company on Track to Report Topline Data Before Year End SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 15, 2019  /  VistaGen Therapeutics  (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2019 / VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced financial results for its fiscal